Bedaquiline (BDQ) use for all age groups in drug-resistant (DR) tuberculosis (TB) regimens for children may be shorter, safer, and more effective. However, the emergence of BDQ resistance reports soon after its introduction is alarming. We report the case of a 17-year-old boy, initially diagnosed with Rifampicin-resistant (RR)-TB and developed BDQ resistance during the treatment. To the best of our knowledge, this is the first report of BDQ resistance in pediatric.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509653 | PMC |
| http://dx.doi.org/10.1016/j.idcr.2023.e01880 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques.
NPJ Antimicrob Resist
December 2024
Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, 98145, USA.
Tuberculosis (TB) killed approximately 1.3 million people in 2022 and remains a leading cause of death from the bacteria Mycobacterium tuberculosis (M.tb); this number of deaths was surpassed only by COVID-19, caused by the SARS-CoV-2 virus.
View Article and Find Full Text PDFTuberculosis vaccines and therapeutic drug: challenges and future directions.
Mol Biomed
January 2025
Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, 17#Heishanhu Road, Haidian District, Beijing, 100091, China.
Tuberculosis (TB) remains a prominent global health challenge, with the World Health Organization documenting over 1 million annual fatalities. Despite the deployment of the Bacille Calmette-Guérin (BCG) vaccine and available therapeutic agents, the escalation of drug-resistant Mycobacterium tuberculosis strains underscores the pressing need for more efficacious vaccines and treatments. This review meticulously maps out the contemporary landscape of TB vaccine development, with a focus on antigen identification, clinical trial progress, and the obstacles and future trajectories in vaccine research.
View Article and Find Full Text PDFEstimating the Early Transmission Inhibition of new treatment regimens for drug-resistant tuberculosis.
J Infect Dis
January 2025
Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, United States.
Introduction: Most drug-resistant tuberculosis (DR-TB) occurs due to transmission of unsuspected or ineffectively treated DR-TB. The duration of treatment to stop person-to-person spread of DR-TB is uncertain. We evaluated the impact of novel regimens, including BPaL, on DR-TB transmission using the human-to-guinea pig (H-GP) transmission model.
View Article and Find Full Text PDFPopulation pharmacokinetics of bedaquiline: a systematic review.
Eur J Clin Pharmacol
January 2025
Department of Pharmacy, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, 310000, Zhejiang, China.
Background And Objectives: Bedaquiline (BDQ) plays a critical role in the treatment of multidrug-resistant tuberculosis (MDR-TB). However, the large pharmacokinetic (PK) variability of BDQ presents a significant challenge in its clinical use. This study aimed to summarize the population PK characteristics of BDQ and to identify significant covariates affecting the PK variation of BDQ.
View Article and Find Full Text PDFFormulation and optimisation of bedaquiline nanoemulsions for the potential treatment of multi drug resistant tuberculosis in paediatrics using quality by design.
Sci Rep
December 2024
Department of Pharmaceutical Science, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, 0204, South Africa.
Bedaquiline is a drug used for the treatment of multidrug-resistant TB in adults and children that is currently only commercially available in tablet form. The present study was aimed at preparing nanoemulsion (NE) of BDQ using natural vegetable oils to deliver BDQ. The optimisation of surfactant mixtures was undertaken using Design of Experiments (DoE), specifically an optimal mixture design.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!